You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
The martial arts novel is one of the most distinctive and widely-read forms of modern Chinese fiction. John Christopher Hamm offers the first in-depth English-language study of this fascinating and influential genre, focusing on the work of its undisputed twentieth-century master, Jin Yong.
The People's Republic of China claims to have 22,000 kilometres of land borders and 18,000 kilometres of coast line. How did this vast country come into being? The state credo describes an ancient process of cultural expansion: border peoples gratefully accept high culture in China and become inalienable parts of the country. And yet, the "centre" had to fight against manifestations of discontent in the border regions, not only to maintain control over the regions themselves, but also to prevent a loss of power at the edges from triggering a general process of regional devolution in the Han Chinese provinces. The essays in this volume look at these issues over a long span of time, questioning whether the process of expansion was a benevolent civilizing mission.
As the outermost barrier of the body, the skin protects against bacterial, viral, and environmental assaults. To reach this end, epidermal and dermal resident cells have evolved intricate communication networks, involving innate and adaptive immune cells, epithelial cells, and neurons. In disease states, skin resident cells are aided by recruited immune cells, such as neutrophils, basophils, and eosinophils. Initially, these cell types were studied in isolation, but recent focus has shifted towards understanding how physical interactions between cells and communication initiated by soluble mediators facilitate coordinated immune responses in the cutaneous microenvironment to maintain homeost...
Despite many years of translational research in breast cancer, very few new biomarkers have been implemented for clinical use beyond estrogen receptor, progesterone receptor, and HER2. The main reason is that many promising biomarkers are clinically validated but lack analytical and clinical utility. One explanation is that proper validation of the predictive ability of the biomarker in independent datasets, and with a pre-planned statistical analysis, is not always performed. Thus, there is a need to identify new biomarkers or new ways to subclassify breast cancer patients that are reproducible and easy to implement in the clinical setting but, more importantly, that improve patient’s outcomes.